This could really move the needle in the GLP-1 weight loss market.

Semaglutide , the active ingredient in Ozempic and Wegovy, is injected into the fatty tissue just under the skin of the stomach, thigh or upper arm to treat obesity or Type 2 diabetes.

Soon, there may be a promising alternative for the needle-averse, as results of a recent Phase 3 trial confirmed that a daily 25-milligram semaglutide pill can trigger significant weight loss. 3

“We all knew this was coming, and we all feel that it could potentially be a game changer in terms of adopting these GLP-1s across the board,” Dr. Armando Castro-Tié — senior vice president and physician executive of Northwell Health’s Eastern Region, who was not involved in this research — told The Post.

In the study , overweight or

See Full Page